J Breast Cancer.  2022 Feb;25(1):69-73. 10.4048/jbc.2022.25.e5.

The Prediction of HER2-Targeted Treatment Response Using ⁶⁴CuTetra- Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report

• Lee I
• Lim I
• Byun BH
• Kim BI
• Choi CW
• Lee KC
• Kang CM
• Seong MK
• Kim HA
• Noh WC
• Lim SM

• KMID: 2526725
• DOI: http://doi.org/10.4048/jbc.2022.25.e5

Abstract

A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy. The patient underwent ⁶⁴ Cu-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography/computed tomography (PET/CT) to evaluate the HER2 expression status.⁶⁴ Cu-DOTA-trastuzumab accumulated in the left breast and lymph nodes but not in the lung lesions. Following trastuzumab emtansine treatment, there was a significant improvement in the lesions with ⁶⁴ Cu-DOTA-trastuzumab accumulation. However, the lesions that did not accumulate ⁶⁴ Cu-DOTA-trastuzumab aggravated. Therefore, it was concluded that ⁶⁴ CuDOTA-trastuzumab PET/CT can be used to predict the outcome of HER2-targeted treatment by evaluating HER2 expression in breast cancer patients.

Keyword

Breast Neoplasms; ⁶⁴ Cu-DOTA-Trastuzumab; ERBB2 Protein; Human; Positron-Emission Tomography